EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): Mechanisms, Clinical Implications and Therapeutic Advances

Dalia M Miller iD, Kiana F McCauley, Kimberly J Dunham-Snary

Endocrinology, Diabetes & Metabolism · 2025-11 · 8 (6)

DOI: 10.1002/edm2.70132 ↗

At a glance

Übersichtsarbeit in Endocrinology, Diabetes & Metabolism, published online on 2025-11-19. Written by Dalia M Miller and 2 co-authors. Institution: Department of Medicine, Queen's University, Kingston, Ontario, Canada. Major MEDLINE topics: Metabolic Diseases, Non-alcoholic Fatty Liver Disease, Liver. Cited 124 times so far (Crossref); 235 references. The full text is freely available (open access, CC BY 4.0). Funded by: CIHR, Tier II Canada Research Chair in Mitochondrial and Metabolic Regulation in Health and Disease, Canada Foundation for Innovation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, affecting ~25%–30% of the adult population, with higher prevalence observed in individuals with obesity and type 2 diabetes. Among reported MASLD cases, prevalence is consistently higher in men than in women, and global incidence has risen by ~50% over the past two decades, mirroring the global rise in obesity and metabolic syndrome. MASLD encompasses a spectrum of hepatic pathologies ranging from simple steatosis to steatohepatitis, fibrosis and cirrhosis. Despite its high prevalence, the heterogeneity in disease progression and relative absence of approved pharmacological therapies pose challenges for effective clinical management. Methods and Results This review synthesises current literature on MASLD across epidemiology, pathophysiology, clinical presentation and treatment. Key molecular mechanisms, including lipid metabolism dysregulation, insulin resistance and mitochondrial dysfunction, are examined with a focus on understanding the basis for progression to metabolic dysfunction‐associated steatohepatitis (MASH). Clinical manifestations, diagnostic tools and risk stratification systems for MASLD are summarised. Current and emerging therapies such as lifestyle interventions, pharmacological agents and microbiome‐targeted strategies are reviewed. The review also highlights ongoing challenges, including diagnostic limitations, disease heterogeneity and disparities in care.

Conclusion

MASLD is a complex, multifactorial liver disease with a growing public health impact, driven by the rising prevalence of metabolic syndrome. Mitochondrial dysfunction is a critical nexus linking genetic susceptibility to metabolic stress and inflammatory responses. Preclinical models that capture these mitochondrial contributions are vital for therapeutic discovery and for advancing personalised medicine approaches in MASLD care.

Subjects

MeSH terms (MEDLINE)

Metabolic DiseasesNon-alcoholic Fatty Liver DiseaseLiverHumansPrevalenceObesityDiabetes Mellitus, Type 2Risk FactorsGastrointestinal AgentsMaleFemaleIncidence

Author keywords

Western‐style dietmitochondrial dysfunction‐associated steatohepatitis (MASH)mitochondrial dysfunction‐associated steatotic liver disease (MASLD)mitochondrial genetics

Substances

Gastrointestinal Agents

Authors and institutions

  • Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Bachelor of Health Sciences Program, Queen's University, Kingston, Ontario, Canada.
  • Department of Biomedical & Molecular Science, Queen's University, Kingston, Ontario, Canada.

ORCID profiles: Dalia M Miller

Funding

  • CIHR
  • Tier II Canada Research Chair in Mitochondrial and Metabolic Regulation in Health and Disease
  • Canada Foundation for Innovation
  • Banting Research Foundation and Mitacs
  • Queen's University, Kingston, Ontario, Canada
  • Canadian Institutes of Health Research

Cite

APA

Miller, D. M., McCauley, K. F., & Dunham-Snary, K. J. (2025). Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): Mechanisms, Clinical Implications and Therapeutic Advances. Endocrinology, Diabetes & Metabolism, 8(6). https://doi.org/10.1002/edm2.70132

Vancouver

Miller DM, McCauley KF, Dunham-Snary KJ. Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): Mechanisms, Clinical Implications and Therapeutic Advances. Endocrinology, Diabetes & Metabolism. 2025;8(6). doi:10.1002/edm2.70132

BibTeX
@article{Miller2025,
  author = {Miller, Dalia M and McCauley, Kiana F and Dunham-Snary, Kimberly J},
  title = {Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): Mechanisms, Clinical Implications and Therapeutic Advances},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2025},
  volume = {8},
  number = {6},
  doi = {10.1002/edm2.70132}
}
Start for free →